For most large employers, the answer to the last question will reveal that 20-40% of generic drug spend is absorbing PBM markup that serves no clinical function
In the STEP 1 (Semaglutide Treatment Effect in People with obesity) extension study, participants regained about twothirds of the weight they had lost with semaglutide within one year, accompanied by declines in cardiometabolic health [140]
Given the role of the caudal hindbrain in emetic/aversive behavior (191) and in mediating GLP-1 effects on food intake (192, 193), these data collectively suggest that GIP potentially acts on the hindbrain-hypothalamus axis to decrease food intake and to improve tolerability of GLP-1R agonism
Moreover, clinicians should reassess lifestyle interventions regularly
In February 2024, Regeneron announced plans to launch a phase 2 trial in mid-2024 that will test combining semaglutide for obesity with either trevogrumab or trevogrumab and garetosmab
This anti-lipogenic activity is hypothesized to involve inhibition of acetyl-CoA carboxylase, the rate-limiting enzyme in de novo lipogenesis
